Patient Characteristics at Study Entry
| Group . | Patient No. . | Age (yr)/Sex . | Histology (REAL) . | Rai Stage . | Years After First Diagnosis . | No. of Prior Therapies . | Lymphocyte Counts (×109/L) . | CD20+ Lymphocytes (%) . | Thrombocyte Counts (×109/L) . |
|---|---|---|---|---|---|---|---|---|---|
| A | 1 | 75/F | B-CLL | II | 2½ | 2 | 0.2 | 92.2 | 175 |
| 2 | 58/F | B-CLL | III | 10 | 5 | 6.5 | 74.0 | 202 | |
| 3 | 56/M | B-CLL | I | 5 | 5 | 7.7 | 93.6 | 314 | |
| 4 | 71/M | B-CLL | III | 4½ | 2 | 11.5 | 15.8 | 14 | |
| 5 | 69/M | B-CLL | IV | 7½ | 5 | 37.2 | 92.9 | 10 | |
| B | 6 | 66/M | B-CLL | IV | 8½ | 3 | 60.8 | 95.7 | 105 |
| 7 | 79/M | Mantle cell NHL | Ann Arbor IV | 5 mo | 2 | 68.1 | 92.8 | 172 | |
| 8 | 59/M | B-CLL | IV | 6½ | 4 | 71.1 | 97.3 | 49 | |
| 9 | 26/F | B-CLL | III | 2½ | 2 | 89.3 | 90.8 | 137 | |
| 10 | 47/M | B-CLL | II | 6½ | 4 | 124.0 | 91.3 | 155 | |
| 11 | 64/F | B-CLL | IV | 2½ | 4 | 294.3 | 70.9 | 74 |
| Group . | Patient No. . | Age (yr)/Sex . | Histology (REAL) . | Rai Stage . | Years After First Diagnosis . | No. of Prior Therapies . | Lymphocyte Counts (×109/L) . | CD20+ Lymphocytes (%) . | Thrombocyte Counts (×109/L) . |
|---|---|---|---|---|---|---|---|---|---|
| A | 1 | 75/F | B-CLL | II | 2½ | 2 | 0.2 | 92.2 | 175 |
| 2 | 58/F | B-CLL | III | 10 | 5 | 6.5 | 74.0 | 202 | |
| 3 | 56/M | B-CLL | I | 5 | 5 | 7.7 | 93.6 | 314 | |
| 4 | 71/M | B-CLL | III | 4½ | 2 | 11.5 | 15.8 | 14 | |
| 5 | 69/M | B-CLL | IV | 7½ | 5 | 37.2 | 92.9 | 10 | |
| B | 6 | 66/M | B-CLL | IV | 8½ | 3 | 60.8 | 95.7 | 105 |
| 7 | 79/M | Mantle cell NHL | Ann Arbor IV | 5 mo | 2 | 68.1 | 92.8 | 172 | |
| 8 | 59/M | B-CLL | IV | 6½ | 4 | 71.1 | 97.3 | 49 | |
| 9 | 26/F | B-CLL | III | 2½ | 2 | 89.3 | 90.8 | 137 | |
| 10 | 47/M | B-CLL | II | 6½ | 4 | 124.0 | 91.3 | 155 | |
| 11 | 64/F | B-CLL | IV | 2½ | 4 | 294.3 | 70.9 | 74 |
Abbreviation: REAL, Revised European American Lymphoma Classification.